Phase II Evaluation of Paclitaxel Infusion in Advanced (Recurrent or Metastatic) Squamous Cell Carcinoma of the Head and Neck

Inclusion Criteria

DISEASE CHARACTERISTICS: Histologically proven squamous cell carcinoma of the head and
neck (including nasopharynx) that is considered incurable with surgery or radiation
therapy Bidimensionally measurable disease Patients whose only site of measurable disease
is within a previous radiation port must have documented progressive disease or
biopsy-proven recurrence after the completion of radiotherapy No uncontrolled CNS
metastases

PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0 or 1 Hematopoietic:
Absolute neutrophil count at least 1,500/mm3 Platelet count at least 100,000/mm3 Hepatic:
Bilirubin no greater than 1.5 mg/dL Renal: Creatinine no greater than 1.5 mg/dL OR
Creatinine clearance at least 60 mL/min Calcium normal No history of hypercalcemia
Cardiovascular: No history of ventricular arrhythmias or symptomatic bradyarrhythmia
Other: No significant detectable infection Not pregnant or nursing No other active
malignancies Fertile patients must use effective contraception

PRIOR CONCURRENT THERAPY: Biologic therapy: Prior interleukin-2, interferons, and
monoclonal antibodies allowed Recovered from prior therapy Chemotherapy: Prior paclitaxel
infusion no greater than 24 hours for recurrent or metastatic disease required Endocrine
therapy: Not specified Radiotherapy: Recovered from prior radiotherapy Surgery: Recovered
from any prior major surgery